← Back to Clinical Trials
Recruiting NCT06667037

NCT06667037 Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06667037
Status Recruiting
Phase
Sponsor Zhongshan Ophthalmic Center, Sun Yat-sen University
Condition Myopia
Study Type INTERVENTIONAL
Enrollment 194 participants
Start Date 2024-09-21
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 8 Years
Max Age 15 Years
Study Type INTERVENTIONAL
Interventions
Ortho-k lenses0.01% Atropine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 194 participants in total. It began in 2024-09-21 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this multicenter randomized clinical trial is to evaluate the myopia control effect of orthokeratology and 0.01% atropine sequential treatment in children and adolescents, as compared to continuous treatment with orthokeratology.

Eligibility Criteria

Inclusion Criteria: 1. Aged 8-15 years old. 2. Spherical equivalent refractions (SERs) -0.50 to -6.00 Dioptres (D) and astigmatism less than -1.5 D in both eyes, anisometropia less than 1.5 D. 3. Best corrected visual acuity (BCVA) equal to or better than 20/25 in both eyes. 4. Bilateral intra-ocular pressure \< 21mmHg. 5. Normal binocular and stereoscopic visual function. 6. Participants and their guardians' understanding and acceptance of random allocation of grouping. Exclusion Criteria: 1. Manifest strabismus, except for intermittent tropia. 2. Ocular or systemic diseases which may affect vision or refractive error. 3. Previous use of myopia control without washout, including atropine, myopia control spectacles, myopia control contact lenses. 4. Other contraindications.

Contact & Investigator

Central Contact

Yin Hu, Doctor

✉ eddy06980094@163.com

📞 86-18664783831

Frequently Asked Questions

Who can join the NCT06667037 clinical trial?

This trial is open to participants of all sexes, aged 8 Years or older, up to 15 Years, studying Myopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06667037 currently recruiting?

Yes, NCT06667037 is actively recruiting participants. Contact the research team at eddy06980094@163.com for enrollment information.

Where is the NCT06667037 trial being conducted?

This trial is being conducted at Guangzhou, China.

Who is sponsoring the NCT06667037 clinical trial?

NCT06667037 is sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. The trial plans to enroll 194 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology